文献速递头颈外科

口腔癌辅助治疗相关的术前临床与肿瘤因素

Preoperative Clinical and Tumor Factors Associated With Adjuvant Therapy for Oral Cavity Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

这项在加拿大9个学术中心开展的队列研究纳入2005年1月至2019年12月接受手术的3980例口腔癌患者,其中1542例(39%)接受辅助治疗。多因素分析显示年龄大于65岁、查尔森共病指数≥4、肿瘤部位、肿瘤大小、临床T和N分期及活检分级等因素与接受辅助治疗独立相关。预测模型区分度良好,受试者工作特征曲线下面积为0.84(95%CI 0.82-0.86)。

要点

  • 3980例口腔癌手术患者中,2438例(61%)仅手术,1542例(39%)接受辅助治疗。
  • 年龄大于65岁(OR 0.50)与接受辅助治疗负相关,查尔森共病指数≥4(OR 1.83)与接受辅助治疗正相关。
  • 预测模型区分度良好,受试者工作特征曲线下面积为0.84(95%CI 0.82-0.86)。

核心结论

  • 这项队列研究结果提示,术前变量有助于识别更可能接受辅助治疗的口腔鳞状细胞癌患者,尽管许多因素直到术后才能预测。
  • 早期识别高风险患者可能改善治疗计划并减少辅助治疗启动延迟,可能改善患者结局。

研究设计与样本

  • 这项队列研究于2005年1月至2019年12月在加拿大9个学术中心开展,是加拿大头颈协作研究倡议的一部分。
  • 参与者为接受手术的口腔癌患者,共3980例,数据分析于2024年3月进行。

主要发现

  • 3980例患者中,2438例(61%)仅接受手术,1542例(39%)接受辅助治疗;1907例(48%)具有辅助治疗的强病理学指征。
  • 平均(标准差)年龄为63(13)岁,1498例参与者(38%)为女性。
  • 多因素分析中与接受辅助治疗独立相关的因素包括:年龄大于65岁(OR 0.50,95%CI 0.38-0.64)、查尔森共病指数≥4(OR 1.83,95%CI 1.26-2.65)、既往头颈癌(OR 0.40,95%CI 0.26-0.62)、上颌牙槽(OR 2.16,95%CI 1.11-4.22)和磨牙后三角(OR 1.85,95%CI 1.04-3.29)亚区、肿瘤尺寸(每厘米OR 1.35,95%CI 1.22-1.50)、临床T和N分期增加以及活检分级更差(低分化:OR 1.89,95%CI 1.25-2.84)。
  • 在接受辅助治疗的患者中,低分化分级(OR 2.40,95%CI 1.34-4.30)和晚期N分期与接受放化疗而非放疗相关。
  • 在具有辅助治疗强病理学指征的患者中,与未接受辅助治疗相关的因素包括年龄、查尔森共病指数、分级、分期和肿瘤尺寸。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The standard of care for patients with oral cavity squamous cell carcinoma (OCSCC) is generally primary surgical resection with or without adjuvant therapy (AT), based on pathological factors. Identifying preoperative factors that are associated with the receipt of AT may enhance treatment planning. OBJECTIVE: To identify preoperative patient and tumor factors associated with receiving AT, either radiation therapy (RT) or chemoradiation therapy (CRT), in patients with OCSCC. DESIGN, SETTING, AND PARTICIPANTS: This cohort study, spanning January 2005 to December 2019 at 9 academic centers in Canada, was conducted as part of the Canadian Head & Neck Collaborative Research Initiative, a national network of head and neck surgical oncologists. Participants included patients with oral cavity cancer who underwent surgery. The data analysis was performed in March 2024. EXPOSURES: Preoperative variables, including demographics (age, sex, smoking history, and Charlson Comorbidity Index [CCI]) and tumor characteristics (clinical T and N stage, biopsy grade, tumor size). MAIN OUTCOMES AND MEASURES: The main outcomes were the receipt of AT vs surgery alone; the type of AT, either RT or CRT; and the presence of a strong pathologic indicator for AT. RESULTS: Of the 3980 patients, 2438 underwent surgery alone (61%) and 1542 received AT (39%). Of these, 1907 (48%) had a strong pathologic indicator for AT. The mean (SD) age was 63 (13) years, and 1498 participants (38%) were female. On multivariable analysis, factors independently associated with AT included being older than 65 years (odds ratio [OR], 0.50 [95% CI, 0.38-0.64]), CCI of 4 or higher (OR, 1.83 [95% CI, 1.26-2.65]), previous head and neck cancer (OR, 0.40 [95% CI, 0.26-0.62]), maxillary alveolus (OR, 2.16 [95% CI, 1.11-4.22]) and retromolar trigone (OR, 1.85 [95% CI, 1.04-3.29) subsites, tumor dimension (OR, 1.35 [95% CI, 1.22-1.50] per cm), increasing clinical T and N stages, and worse grade on biopsy (poorly differentiated: OR, 1.89 [95% CI, 1.25-2.84]). Among those receiving AT, poorly differentiated grade (OR, 2.40 [95% CI, 1.34-4.30]) and advanced N stage were associated with CRT rather than RT. Among patients with strong pathologic indicators for AT, factors associated with not receiving AT included age, CCI, grade, stage, and tumor dimension. The prediction model showed good discriminatory power (area under the receiver operating characteristic curve, 0.84 [95% CI, 0.82-0.86]). CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that preoperative variables can help to identify patients with OCSCC who are more likely to receive AT, despite many factors not being predictable until the postoperative period. Early identification of patients at high risk may improve treatment planning and reduce delays in initiating AT, potentially enhancing patient outcomes.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Dayan GS, Bahig H, Colivas J, et al. Preoperative Clinical and Tumor Factors Associated With Adjuvant Therapy for Oral Cavity Cancer. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40146171. doi:10.1001/jamaoto.2024.5250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。